[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510043":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":38,"responsibleParty":73,"collaborators":26,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":26,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":26,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":26,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MTX and corticosteroid","EXPERIMENTAL","Methylprednisolone 2 mg\u002Fkg\u002Fday was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg\u002Fkg\u002Fday prednisone (or 0.2mg\u002Fkg\u002Fday methylprednisolone). MTX (5mg\u002Fm\\^2\u002Fday) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR.",[13],"Drug: MTX",{"label":15,"type":16,"description":17,"interventionNames":18},"Corticosteroid","ACTIVE_COMPARATOR","Methylprednisolone 2 mg\u002Fkg\u002Fday was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg\u002Fkg\u002Fday prednisone (or 0.2mg\u002Fkg\u002Fday methylprednisolone).",[19],"Drug: Corticosteroid",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","MTX","MTX (5mg\u002Fm\\^2\u002Fday) was given on days 1, 3, and 8, and repeated weekly until aGVHD was CR",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Corticosteroid Methylprednisolone 2 mg\u002Fkg\u002Fday was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg\u002Fkg\u002Fday prednisone (or 0.2mg\u002Fkg\u002Fday methylprednisolone).",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Yu Wang, M.D.","CONTACT","86-13552647384","ywyw3172@sina.com",{"name":37,"role":33,"phone":26,"phoneExt":26,"email":26},"Xiao-Jun Huang, M.D.",[39,57],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Peking University Institute of Hematology,","RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":48,"coordinates":49},"Point",[50,51],116.39723,39.9075,{"lat":51,"lon":50},[54],{"name":55,"role":33,"phone":56,"phoneExt":26,"email":35},"Yu Wang, Dr.","13552647384",{"facility":58,"status":41,"city":59,"state":60,"zip":61,"country":45,"countryCode":46,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Nanfang Hospital, Nanfang Medical University","Guangzhou","Guangdong","510515",{"type":48,"coordinates":63},[64,65],113.25,23.11667,{"lat":65,"lon":64},[68,71],{"name":69,"role":33,"phone":26,"phoneExt":26,"email":70},"qifa liu, M.D.","liuqifa628@163.com",{"name":69,"role":72,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":72,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Xiao-Jun Huang","director, hematology department,Peking University People's Hospital","100510043","phase-3-mini-dose-mtx-plus-standard-dose-steroid-for-the-initial-treatment-of-acute-gvhd-100510043",false,"NCT05921305","Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD","Randomized Trial of Mini-dose Methotrexate Plus Standard-dose Steroid vs Steroids for the Initial Treatment of Acute Graft Versus Host Disease","Inclusion Criteria:\n\n1. Patients who are fully informed and sign informed consent by themselves or their guardians;\n2. Patients receiving first allogeneic hematopoietic stem cell transplantation;\n3. Patients with acute graft-versus-host disease of grade II-IV were diagnosed after transplantation;\n4. KPS\\>60, Estimated survival \\>3 months;\n5. No serious organ damage:\n\n   1. ANC in peripheral blood is greater than 0.5×109\u002Fl\n   2. Creatinine \\\u003C 1.5mg\u002Fdl\n   3. Cardiac ejection index \\> 55%\n\nExclusion Criteria:\n\n1. Patients with severe brain, heart, kidney or liver dysfunction unrelated to graft-versus host disease;\n2. Patients with uncontrollable active infection;\n3. Patients with recurrence of primary malignant hematopathy;\n4. Expected survival is less than 3 months\n5. Patients who have histories of severe allergic reactions\n6. Pregnant or lactating women\n7. The researcher judges that there are other factors that are not suitable for participating\n8. Patients who received donor lymphocyte infusion","ALL","15 Years","65 Years",{"count":87,"type":88},218,"ESTIMATED","INTERVENTIONAL",[91],"PHASE3","This trial is a randomized (1:1) phase III open label study of frontline mini-MTX plus methylprednisolone 2mg\u002Fkg\u002Fday compared to methylprednisolone 2mg\u002Fkg in allogeneic stem cell transplant recipients with grade 2-4 aGVHD.",[94],"Acute Graft Versus Host Disease","2025-05-28",{"date":97,"type":98},"2025-06-03","ACTUAL",{"date":100,"type":98},"2023-08-03",{"date":102,"type":88},"2026-09-30",{"name":5,"class":6},2]